food and drug administration has expanded the imapproval of the novartis cancer drug, kisqali.atients can now access the drug which can help prevent the cancer from returning. that i see promises with that clinical trial with the reduction of the risk of kabser 25% after three years and 28.5% after four years. the ceo told cnbc this is good news. >> kisqali will be the only drug to patients with the so-called intermediate risk to the cancer. these are patients with no nodes or single-node cancer. it's also important to note that k kisqali is the leader. this could be one of novartis's largest drugs over time. >> let's take a closer look at the pharmaceutical sector. joining us now, joachim kreuzburg. good morning and good to have you on the show. your shares are down almost 30% over the last 12 months. what's going on. why are you failing to conviction investors? >> good morning, everyone, and thanks for having us. so, yeah, share price, indeed, is down in comparison to the previous year because we're still in a year of transition because customers have set themselves more ambi

novartis is making it work with its drugs.rmaceuticals manufacturing and it's paying off. they are estimated to bring in $4 billion a year by 2027. novartis and other companies telling me the real opportunity is to expand to many different types of cancer. but the trick is finding markers that are on cancer cells and not unhealthy ones. there's no guarantee they'll be able to thread that needle but there's a lot of excitement here, carl. >> is production as challenged as it is in weight loss at the moment? >> it's really different because you need to make the drug right before you give it to the patient. there's no inventory and it looks a lot different. eli lilly telling me that you go into a weight loss manufacturing facility and you see a lot more. there's less to see at the radio pharmaceutical manufacturing facility but it is still a really complicated production. >> the general take is a lot is about thematic discipline, the way lilly stuck with diabetes for 30 years and wound up with this pressure. is novartis the equiv

again, novartis is the leader here. they have two drugs.ers, they're far along, acquired a company for $4 billion. and that's pretty far along. we also have astrazenica, eli lilly, and sanofe getting in on it, too. >> are they in the space or in the space they're trying to help with the symptoms of -- >> no, pfizer, they're working on a different drug to. patients who are -- they have something called cancer caxia, where you lose your appetite and that leads to muscle wasting. and that's a problem, you lose a lot of weight, and it can make your symptoms even worse. so they over this weekend presented some data showing that their experimental drug can help. that's something we'll be watching, as well. >> always nice to hear. i know the stuff is expensive and whatnot, but for people dealing with these -- if they could do something like you said for lung and breast, that would be great. >> thank you very much. appreciate it. >> thank you. >>> wall street has its eye on wednesday's fed decision on interest rates. we will bring you three differe

el medicamento se llama cali y su fabricante, novartis anunciÓ hoy que la fda extendiÓ la aprobaciÓn,sultados de una investigaciÓn publicada en el diario de endocrinologÍa y metabolismo. no obstante, hay que tener cuidado de no rebasar cierta cantidad de cafeÍna por los efectos en la salud y hay en el mundo explosiÓn de beepers deja muertos y miles de heridos. arrestan a un estadounidense en venezuela acusado de complot y tambiÉn el escalofriante testimon del hom el cambio está en el aire. el virus que causa covid-19 ha cambiado, por lo que las vacunas contra covid-19 han cambiado también. ponerte la vacuna contra covid-19 de esta temporada ayuda a protegerte al entrenar tu sistema inmunológico a reconocer y combatir las variantes recientes. los cdc recomiendan ponerte las vacunas contra covid y la influenza en la misma consulta si te tocan las dos. pregúntale a tu farmacéutico o a tu médico acerca de recibir la vacuna contra covid-19 de esta temporada junto con la de la influenza. switch to shopify so you can build it better, scale it faster and sell more. much more. take your busine

drugmaker novartis says kisqali can now be used to treat patients in earlier stages of the disease.e risk of a patient's cancer returning by up to 25% in the first three years. >>> a rare lunar trifecta tonight. a super harvest blood moon. this year's harvest moon is also a super moon, and a blood moon, which will occur during tonight's partial eclipse. it peaks at about 10:44 eastern. >>> when we come back here tonight, the remarkable story. high school sweethearts, and what they decided to do so many years ago, and what's now happened tonight. un meyer the hatter for over 75 years now. 99 years old and he'd come five days a week if we let him. shape is great, the color's nice, that's a swell lid for you, baby! finding the exact date on ancestry that our family business was founded, really struck a chord with my grandfather. i've never seen this before. look at it - where has this come from? all the stories that's he's been able to hand me throughout the years, for me to hand him that information.. you don't get that moment every day. ♪fun music♪ mom, can i help? camping was fun, b

vaknar has done in terms of righting novartis.and gets the wrath of goldman that takes it from buy to hold. they say it moves too much. i hope it comes down and people buy it. nice calls on "mad money" and things i've done right. i had this in my -- i had this in my bull pen and didn't pull the trigger. i thought it was an unsustainable rally and that was wrong and it's going to continue here. very good company. >> it's the latest in a collection of names where you had a nice run and you were unwilling to let go. >> yes. >> we mentioned coke and talked proctor. we let go of a little bit of proctor. look what i did in alphabet. alphabet has a big trial that starts on monday about advertising and i think of the government is on the wrong side, but that hasn't meant much. i think they had a better case with the default search. i have held on to alphabet too long. it's been a bear, and when it was down the most of any stock during -- it was down by 4 or 5 in the daily i did this chart of daily losses and this company came up, the only

g g right now, novartis has two pharmaceuticals for some tumors.tain radioactive material that is good for a few days. you need to get them into patients asap. one requires extra work, but it is paying off and he sees a brighter future ahead. >> the platform is there and as, you know, drug development can create a new molecule combined to the cancer cell, i think there will be more drugs that may be used for more condition, you know, certainly coming in the future. >> a lot of the drugs are in the early stages of development. it could be a while before we know the true potential. astrazeneca representatives say this could be important for cancer care into the 2030s. >> this is a long time. a lot of times they try to put the radio isotope with the monoclonal. do you know what the mechanism is in this case? >> what is happening here is you have the drugs that look for a marker. the drug goes there and delivers the radiation to the different isotopes. what is important here is you are taking the cancer and bringing the radiation to the cells and spari